Cancer kills 10 million people a year. The war against it is being fought with more money, more intelligence, and more success than ever before. Here are six companies at the centre of that fight — and an honest account of what investing in them actually involves.
Cancer kills 10 million people a year. The war against it is being fought with more money, more intelligence, and more success than ever before. Here are six companies at the centre of that fight — and an honest account of what investing in them actually involves.
There’s a particular kind of investment thesis that cuts through the noise — one where you don’t need to believe in a trend or a narrative. You just need to look at the data. Cancer kills around 10 million people a year. Governments spend more on oncology research than any other disease area. The pharmaceutical industry directs more capital toward cancer drugs than any other therapeutic category. And the science is advancing at a pace that would have seemed impossible twenty years ago.
This isn’t a speculative bet on a technology that might one day work. It’s an observation that the war on cancer is being fought with more resources, more intelligence, and more success than at any point in human history — and that the companies leading that fight are, in many cases, extraordinary businesses.
That doesn’t make them easy investments. Oncology is arguably the most technically demanding sector in all of equity markets. A single Phase 3 trial failure can destroy years of gains overnight. Regulatory decisions are binary. The difference between a $40 stock and a $4 stock can be a single FDA complete response letter. Anyone who tells you oncology investing is straightforward is either naive or trying to sell you something.
What it is, though, is worth understanding. Because the companies that get this right — that bring genuinely effective treatments to patients who previously had no options — tend to build extraordinary, durable value. Here are six worth knowing.
“The companies that get oncology right don’t just build great businesses. They change what it means to be diagnosed with cancer.”
The global cancer treatment market is projected to exceed $500 billion by 2030. That’s not a prediction built on hope — it’s a projection built on demographics (ageing populations get more cancer), science (new treatment modalities are opening up markets that didn’t exist a decade ago), and pricing dynamics (effective cancer drugs command prices that most other medicines can’t).
The most important development of the past five years has been the emergence of antibody-drug conjugates — targeted delivery systems that attach a cytotoxic payload to an antibody designed to find cancer cells. Think of them as guided missiles rather than carpet bombs. They’ve shown efficacy in cancer types that previously had very limited options, and every major pharma company is now racing to build an ADC portfolio.
Alongside ADCs, cell therapies — particularly CAR-T and, more recently, TIL (tumour-infiltrating lymphocyte) therapies — are delivering remarkable results in patients who have exhausted other options. The FDA’s approval of the first TIL therapy in 2024 marked a turning point that most investors have still not fully priced in.
And then there’s early detection. The idea that a single blood test could scan your DNA for evidence of 50 different cancer types — before symptoms, before it’s too late — is not science fiction. It’s here. It’s being sold. The question is how fast the healthcare system will pay for it.
Clinical trial failures are common, brutal, and often unpredictable. A Phase 3 failure in a single-asset biotech typically results in a 60–80% share price decline in a single session. Even in diversified large-caps, a major pipeline setback can wipe significant value.
Regulatory risk is real and binary. The FDA can — and does — reject applications that the market had priced as near-certain approvals. It can request additional data that delays revenue by two years.
The implication for portfolio construction: oncology positions should be sized conservatively unless you have genuine conviction in a specific pipeline event. For most investors, a mix of large-cap names and an ETF is more sensible than concentrated individual bets.
The company that reinvented itself — and became the gold standard for oncology investing.
Fifteen years ago, AstraZeneca was a company in trouble — a dwindling pipeline, patent cliffs looming, and serious questions about its long-term relevance. What happened next is one of the great corporate turnaround stories in modern pharma. The company bet heavily on oncology, rebuilt its R&D engine, and is now home to some of the most important cancer drugs on the market.
Tagrisso transformed the treatment of EGFR-mutated non-small cell lung cancer. Lynparza, developed with Merck, established PARP inhibition as a standard-of-care approach across multiple cancer types. But the most exciting asset is Enhertu — an antibody-drug conjugate co-developed with Daiichi Sankyo that has shown efficacy in breast cancer, lung cancer, and gastric cancer, often in patients where other treatments had failed.
Enhertu’s clinical data have been described by oncologists as paradigm-shifting. When a drug starts showing meaningful survival benefits in previously untreatable populations, that language matters. AstraZeneca’s oncology pipeline contains over 20 compounds in late-stage development — the kind of breadth that insulates investors from the worst of binary trial risk.
For investors, AstraZeneca offers something genuinely rare: large-cap stability combined with genuine growth. It’s not cheap. But it’s earned its premium.
Everyone knows it for GLP-1. The oncology story is just beginning.
The conversation about Eli Lilly almost always starts — and often ends — with Mounjaro and Zepbound, the GLP-1 drugs that have made it one of the most valuable companies in the world. That’s understandable. The obesity franchise is a generational revenue opportunity. But it also obscures something important: Lilly’s oncology business is quietly becoming one of the most interesting in pharma.
Verzenio (abemaciclib) for breast cancer has crossed $4 billion in annual sales and continues to grow as it expands into earlier treatment settings. Jaypirca for B-cell malignancies is a newer growth driver. And Lilly’s ADC pipeline — still in relatively early stages — is being built with the kind of capital and scientific talent that only a company generating Lilly’s current cash flows can deploy.
The structural advantage is simple: Lilly’s metabolic franchise generates the cash that funds aggressive oncology R&D. It doesn’t have to choose between investing in the pipeline and keeping the lights on. That’s a luxury that most oncology biotechs simply don’t have.
The company that made history — and is now trying to build a business on it.
In February 2024, Iovance became the first company in history to win FDA approval for a tumour-infiltrating lymphocyte therapy. The drug — Amtagvi (lifileucel) — treats advanced melanoma in patients who have already failed prior treatments. For patients who had essentially run out of options, it offered something genuinely new: a treatment that works by extracting the patient’s own immune cells from their tumour, expanding them in a laboratory, and reinfusing them to fight the cancer.
The approval validated years of scientific work on TIL therapy and opened a new chapter in immuno-oncology. It also created a significant commercial challenge. TIL therapy is extraordinarily complex to manufacture — each treatment is essentially custom-made for each patient. The supply chain, the logistics, the training of oncology centres to administer it: all of this has to be built from scratch alongside the science.
Iovance is in the earliest stages of that buildout. Revenue is growing. The pipeline includes cervical cancer and non-small cell lung cancer programmes that, if successful, would dramatically expand the addressable market. This is not a safe investment. But for investors who believe in the platform and can stomach the uncertainty, it’s one of the more compelling stories in early-commercial oncology.
“For patients who had run out of options, TIL therapy offered something the oncology world hadn’t seen before — a treatment that uses the cancer itself to fight back.”
The test that could change cancer medicine entirely — if the healthcare system will pay for it.
The single most powerful intervention in cancer medicine is catching it early. Stage I cancer survival rates are dramatically higher than Stage IV for almost every cancer type. The problem has always been that most cancers don’t produce symptoms until they’re well advanced. By the time you feel something, it’s often too late for easy treatment.
Grail’s Galleri test addresses this directly. A single blood draw analyses circulating tumour DNA in the bloodstream and can detect over 50 types of cancer — identifying not just the presence of cancer signal but the tissue of origin, with approximately 90% accuracy. The false positive rate is just 0.5%. These are extraordinary numbers for a screening technology.
The commercial reality is more complicated. Galleri costs around $950 and is not yet covered by most insurance plans. Without reimbursement, the addressable market is limited to people who can and will pay out of pocket — a large number in absolute terms, but a fraction of the population that could benefit. Grail is investing heavily in the clinical evidence needed to change that. Revenue grew 43% year-on-year in Q2 2024. Profitability is years away.
This is a long-duration, high-conviction bet. The question is not whether early cancer detection is valuable — it obviously is. The question is how fast the healthcare system will structure itself to pay for it, and whether Grail can survive long enough to find out.
Quietly building one of the most impressive cancer pipelines in large-cap biotech.
Regeneron doesn’t get the same oncology headlines as AstraZeneca or Lilly, but it probably should. Libtayo (cemiplimab) — the company’s PD-1 checkpoint inhibitor — has secured approvals in skin cancers, cervical cancer, and non-small cell lung cancer, and is building a meaningful commercial presence in markets where Merck’s Keytruda and Bristol-Myers’ Opdivo have long dominated.
More importantly, Regeneron’s bispecific antibody platform is generating a pipeline of novel cancer treatments that could meaningfully differentiate it from checkpoint inhibitor competitors. Bispecifics — antibodies engineered to bind two different targets simultaneously — are one of the most active areas of cancer drug development, and Regeneron’s scientific capabilities in antibody engineering are genuinely world-class.
The company’s financial discipline is also worth noting. It has consistently delivered pipeline productivity while maintaining a strong balance sheet and returning capital to shareholders. For investors who want quality large-cap oncology exposure without the execution uncertainty of earlier-stage companies, Regeneron belongs in the conversation alongside AstraZeneca.
Precision oncology done properly — targeting the mutation, not just the cancer.
Blueprint Medicines is built on a simple but powerful idea: instead of treating lung cancer or breast cancer as single diseases, treat the specific genetic mutation driving each patient’s tumour. This is precision oncology in its purest form — and Blueprint has executed it with unusual clarity and focus.
Its flagship drug Ayvakit (avapritinib) treats two very different conditions: GIST (gastrointestinal stromal tumours) with specific PDGFRA mutations, and systemic mastocytosis — a rare mast cell disease where Ayvakit has shown response rates that were simply not achievable with prior treatments. Patients who previously had a median survival measured in months are now achieving durable remissions.
Blueprint reached profitability in 2024 — a milestone that fundamentally changes the risk profile. It no longer needs to go to the capital markets to fund its operations, which removes the dilution risk that haunts so many biotechs. Its pipeline targets additional kinase-driven cancers, expanding the addressable population while staying true to the precision oncology model that defines the company.
Blueprint is not a household name. It operates in small patient populations with orphan-drug designations. But the commercial execution has been strong, the science is rigorous, and the recently achieved profitability is a significant de-risking event for new investors.
There is no shame in acknowledging that individual oncology stock picking is genuinely hard. You need to understand clinical trial design, competitive dynamics, FDA regulatory pathways, and pricing environments — all while making probabilistic judgments about outcomes that even expert oncologists can’t reliably predict. If that’s not something you want to spend time on, a cancer treatment ETF is a perfectly sensible alternative.
| ETF | Ticker | Focus | Expense Ratio |
|---|---|---|---|
| Tema Oncology ETF | CANC | Pure-play oncology companies | ~0.75% |
| Range Cancer Therapeutics ETF | CNCR | Cancer therapeutics | ~0.79% |
| iShares Genomics Immunology & Healthcare ETF | IDNA | Genomics, immunology, oncology | ~0.47% |
| ARK Genomic Revolution ETF | ARKG | Genomics, biotech, precision medicine | ~0.75% |
“The science is advancing faster than at any point in human history. For patient, informed investors, oncology remains one of the most exciting places to be.”
Whatever approach you take, the underlying premise holds. Cancer research is not going to slow down. The companies finding better ways to treat it are not going to become less valuable. The challenge — and the opportunity — is in identifying which of those companies will still be standing, and winning, when it matters.
Disclaimer: This article is editorial analysis only and does not constitute financial or investment advice. Pharmaceutical and biotech investments carry significant risk. Always conduct your own research and consider seeking independent financial advice before investing.